Suggested Topics within your search.
Suggested Topics within your search.
-
2121
-
2122
Choline Alphoscerat (Gliatilin) in the pathogenetic therapy of Alzheimer’s disease
Published 2019-02-01Get full text
Article -
2123
Cardioneuroablation in the treatment of neurocardiogenic syncope and functional bradyarrhythmias. A literature review
Published 2025-02-01“…We conducted a descriptive review of the most significant publications on effectiveness and development of the cardiac neuroablation technique in patients with vasovagal syncope and neurogenic functional bradyarrhythmias — sinus node dysfunction and atrioventricular conduction disorders. …”
Get full text
Article -
2124
Recent advances in anterior pituitary hormones and metabolic-associated fatty liver disease
Published 2025-07-01Get full text
Article -
2125
-
2126
-
2127
-
2128
Transcriptomic evidence for atopic dermatitis as a systemic disease in NC/Nga mice
Published 2024-11-01Get full text
Article -
2129
-
2130
RECURRENT CORNEAL EROSION SYNDROME (a review)
Published 2015-07-01“…Other causes or factors which increase the risk of RCE syndrome include meibomian gland dysfunction, keratoconjunctivitis sicca, diabetes, and post-LASIK conditions. …”
Get full text
Article -
2131
Endothelial function can be modulated by acute hyperglycemia
Published 2025-08-01“…Abstract Endothelial dysfunction is a known consequence of chronic hyperglycemia and a major pathogenic factor for microvascular diseases such as diabetic retinopathy. …”
Get full text
Article -
2132
The Angiogenic Markers PlGF and sFlt-1 in Cytomegalovirus Infection During Pregnancy: Insights from a Clinical Case
Published 2025-02-01“…CMV placental infection can contribute to the development of adverse outcomes likely through placental dysfunction. This case report shows the potential utility of angiogenic markers, such as placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1), in assessing CMV-related placental involvement and monitoring the effect of antiviral therapy on placental function, and highlights the possibility of integrating these markers into the clinical management of CMV infection.…”
Get full text
Article -
2133
Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies
Published 2016-06-01“…Anita H Clayton,1 Suresh Durgam,2 Xiongwen Tang,2 Changzheng Chen,2 Adam Ruth,3 Carl Gommoll2 1Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, 2Forest Research Institute, Jersey City, NJ, 3Prescott Medical Communications Group, Chicago, IL, USA Background: Vilazodone has been shown to reduce core symptoms of generalized anxiety disorder (GAD) in three randomized, double-blind, placebo-controlled trials. Since sexual dysfunction (SD) is not well characterized in GAD, a post hoc analysis of these trials was conducted to evaluate the effects of vilazodone on sexual functioning in GAD patients. …”
Get full text
Article -
2134
Prognostic value of vascular remodeling parameters in the development of adverse cardiovascular events in patients with gastric cancer
Published 2022-12-01“…In this study, for the first time, a comprehensive assessment of the effect of MAC on endothelial dysfunction and vascular stiffness, including, in the long-term follow-up period, was carried out in patients with gastric cancer. …”
Get full text
Article -
2135
Reproductive aging in farm animals: Impacts on fertility and strategies for mitigation: A narrative review
Published 2025-01-01“…This decline is exacerbated by oxidative stress and mitochondrial dysfunction, leading to reproductive senescence and reduced offspring viability. …”
Get full text
Article -
2136
-
2137
DEPARETIC PHENOMENON DURING UNDERWATER LUMBAR EXTENSION
Published 2025-05-01“…The purpose of this study is to evaluate the effect of underwater lumbar extension on the motor dysfunction of the paretic leg of a patient with a herniated disk and the patient's recovery rate after the treatment. …”
Get full text
Article -
2138
-
2139
Precision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series)
Published 2025-01-01Get full text
Article -
2140